ClinicalTrials.Veeva

Menu

Assessment of Ventilation-perfusion Abnormalities in Patients With Stable Smoking-related Airways Disease

Imperial College London logo

Imperial College London

Status

Terminated

Conditions

Chronic Obstructive Pulmonary Disease

Treatments

Drug: salbutamol + ipratropium bromide nebules
Drug: nebulized saline

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT00180843
04/6741

Details and patient eligibility

About

Subjects undergo history, examination, lung function assessment after informed consent has been obtained. All subjects will undergo ventilation-perfusion scans. If there first scan is normal they will undergo a second and final scan four weeks later. If abnormal they will undergo two further scans with either nebulized bronchodilator or nebulized saline prior to their second and third scans. Each time they will have repeat lung function tests prior to scanning. We will examine the regional changes in ventilation and perfusion and there relationship to lung function.

Full description

As in Brief description

Enrollment

2 patients

Sex

All

Ages

35 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • FEV1 < 70% predicted at baseline on spirometry
  • significant smoking history or alpha 1 antitrypsin deficiency
  • no evidence of current infection or restrictive lung disease

Exclusion criteria

  • history of other significant respiratory disease
  • significant respiratory infection within 6 weeks
  • history of significant physical or mental illness rendering them unfit for the study in the opinion of the investigator
  • taken part in any other research within the past 12 months, or received exposure to ionizing radiation

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Single Group Assignment

Masking

Double Blind

2 participants in 2 patient groups, including a placebo group

saline control
Placebo Comparator group
Description:
nebulized saline
Treatment:
Drug: nebulized saline
salbutamol and ipratropium bromide nebules
Active Comparator group
Description:
salbutamol 2.5 mg and ipratropium bromide 0.5 mg
Treatment:
Drug: salbutamol + ipratropium bromide nebules

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems